Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001628280-20-011644
Filing Date
2020-08-04
Accepted
2020-08-04 16:37:35
Documents
75
Period of Report
2020-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q xfor-20200630.htm   iXBRL 10-Q 2183620
2 EX-31.1 ex-311q22020.htm EX-31.1 10898
3 EX-31.2 ex-312q22020.htm EX-31.2 10879
4 EX-32.1 ex-321q22020.htm EX-32.1 9447
10 xfor-20200630_g1.jpg GRAPHIC 70840
  Complete submission text file 0001628280-20-011644.txt   8309467

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT xfor-20200630.xsd EX-101.SCH 61868
6 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT xfor-20200630_cal.xml EX-101.CAL 79764
7 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT xfor-20200630_def.xml EX-101.DEF 210884
8 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT xfor-20200630_lab.xml EX-101.LAB 644159
9 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT xfor-20200630_pre.xml EX-101.PRE 386837
11 EXTRACTED XBRL INSTANCE DOCUMENT xfor-20200630_htm.xml XML 1362329
Mailing Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139
Business Address 955 MASSACHUSETTS AVENUE 4TH FLOOR CAMBRIDGE MA 02139 857-529-8300
X4 Pharmaceuticals, Inc (Filer) CIK: 0001501697 (see all company filings)

EIN.: 273181608 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38295 | Film No.: 201073838
SIC: 2836 Biological Products, (No Diagnostic Substances)